Literature DB >> 12019915

Cost-effectiveness analysis of the russian treatment scheme for tuberculosis versus short-course chemotherapy: results from Tomsk, Siberia.

B Jacobs1, C Clowes, F Wares, V Polivakho, T Lyagoshina, G Peremitin, N Banatvala.   

Abstract

SETTING: Tomsk Oblast, Siberia.
OBJECTIVE: To assess the cost-effectiveness of individualised Russian treatment and short-course chemotherapy (SCC) regimens for new WHO Category I tuberculosis patients.
DESIGN: Analysis of costs incurred by the provider, the household and society as a whole for both treatment approaches, and a sensitivity analysis for SCC with hospitalisation for 2 weeks (patients theoretically at low risk of defaulting) and 2 months (patients theoretically at risk of defaulting). Outcomes were measured as cost per case cured and year of life saved, with cure rates based on a locally conducted trial.
RESULTS: The cost per cure using the individualised Russian treatment was US $2,295, vs. US $1,901 when using SCC. The costs per year of life saved were respectively US $123 and US $103. The cost per cure was US $1,457 for SCC with 2 months hospitalisation and US $556 for SCC with 2 weeks hospitalisation, with costs per year of life saved of US $79 and US $30, respectively.
CONCLUSION: Major financial savings for both the provider and the household, with cure rates similar to those obtained with the Russian treatment scheme, can be achieved in Tomsk when embarking on SCC with 2 weeks and 2 months hospitalisation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019915

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  6 in total

1.  Household costs of illness during different phases of tuberculosis treatment in Central Asia: a patient survey in Tajikistan.

Authors:  Raffael Ayé; Kaspar Wyss; Hanifa Abdualimova; Sadullo Saidaliev
Journal:  BMC Public Health       Date:  2010-01-18       Impact factor: 3.295

2.  Cost-effectiveness of treating multidrug-resistant tuberculosis.

Authors:  Stephen C Resch; Joshua A Salomon; Megan Murray; Milton C Weinstein
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

Review 3.  Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.

Authors:  Yoko V Laurence; Ulla K Griffiths; Anna Vassall
Journal:  Pharmacoeconomics       Date:  2015-09       Impact factor: 4.981

4.  Cost minimization analysis of line probe assay for detection of multidrug-resistant tuberculosis in Arkhangelsk region of Russian Federation.

Authors:  E N Bogdanova; A O Mariandyshev; G A Balantcev; P I Eliseev; E I Nikishova; A I Gaida; D Enarson; A Detjen; R Dacombe; P P J Phillips; S B Squire; E Gospodarevskaya
Journal:  PLoS One       Date:  2019-01-29       Impact factor: 3.240

5.  A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology.

Authors:  Lucy Cunnama; Gabriela B Gomez; Mariana Siapka; Ben Herzel; Jeremy Hill; Angela Kairu; Carol Levin; Dickson Okello; Willyanne DeCormier Plosky; Inés Garcia Baena; Sedona Sweeney; Anna Vassall; Edina Sinanovic
Journal:  Pharmacoeconomics       Date:  2020-08       Impact factor: 4.981

Review 6.  Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review.

Authors:  Tadayuki Tanimura; Ernesto Jaramillo; Diana Weil; Mario Raviglione; Knut Lönnroth
Journal:  Eur Respir J       Date:  2014-02-13       Impact factor: 16.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.